相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering
Li Li et al.
SCIENCE ADVANCES (2023)
Off-the-Shelf Prostate Stem Cell Antigen-Directed Chimeric Antigen Receptor Natural Killer Cell Therapy to Treat Pancreatic Cancer
Kun-Yu Teng et al.
GASTROENTEROLOGY (2022)
Phase I Trial Characterizing the Pharmacokinetic Profile of N-803, a Chimeric IL-15 Superagonist, in Healthy Volunteers
Mark P. Rubinstein et al.
JOURNAL OF IMMUNOLOGY (2022)
Inability of granule polarization by NK cells defines tumor resistance and can be overcome by CAR or ADCC mediated targeting
Jiri Eitler et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)
Reengineering Tumor Microenvironment with Sequential Interleukin Delivery
Marxa L. Figueiredo et al.
BIOENGINEERING-BASEL (2021)
Trans-endocytosis of intact IL-15Rα-IL-15 complex from presenting cells into NK cells favors signaling for proliferation
Olga M. Anton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
UniCAR-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells
Nicola Mitwasi et al.
SCIENTIFIC REPORTS (2020)
Establishment of a simple and efficient platform for car-t cell generation and expansion: from lentiviral production to in vivo studies
Virginia Picanco-Castro et al.
HEMATOLOGY TRANSFUSION AND CELL THERAPY (2020)
IL15 by Continuous Intravenous Infusion to Adult Patients with Solid Tumors in a Phase I Trial Induced Dramatic NK-Cell Subset Expansion
Kevin C. Conlon et al.
CLINICAL CANCER RESEARCH (2019)
Cord blood NK cells engineered to express IL-15 and a CD19-targeted CAR show long-term persistence and potent antitumor activity
E. Liu et al.
LEUKEMIA (2018)
Phosphoinositide-3-Kinase Signaling in Human Natural Killer Cells: New insights from Primary immunodeficiency
Emily M. Mace
FRONTIERS IN IMMUNOLOGY (2018)
Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies
Paulina Nowakowska et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2018)
Immunosenescence: limitations of natural killer cell-based cancer immunotherapy
Raquel Tarazona et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2017)
CD56bright NK cells exhibit potent antitumor responses following IL-15 priming
Julia A. Wagner et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56bright NK Cells and Increases NK-Cell Cytokine Release Capabilities
Sigrid Dubois et al.
CANCER IMMUNOLOGY RESEARCH (2017)
NK-92: an 'off-the-shelf therapeutic' for adoptive natural killer cell-based cancer immunotherapy
Garnet Suck et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Selection and expansion of natural killer cells for NK cell-based immunotherapy
Petra S. A. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Lag-3, Tim-3, and TIGIT: Co-inhibitory Receptors with Specialized Functions in Immune Regulation
Ana C. Anderson et al.
IMMUNITY (2016)
CD19-CAR engineered NK-92 cells are sufficient to overcome NK cell resistance in B-cell malignancies
Annette Romanski et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Natural Killer Cells for immunotherapy-Advantages of the NK-92 Cell Line over Blood NK Cells
Hans Klingemann et al.
FRONTIERS IN IMMUNOLOGY (2016)
IL-15-PI3K-AKT-mTOR: a critical pathway in the life journey of natural killer cells
Alaa Kassim Ali et al.
FRONTIERS IN IMMUNOLOGY (2015)
Selective Inhibition of Tumor Growth by Clonal NK Cells Expressing an ErbB2/HER2-Specific Chimeric Antigen Receptor
Kurt Schönfeld et al.
MOLECULAR THERAPY (2014)
Are natural killer cells superior CAR drivers?
Hans Klingemann
ONCOIMMUNOLOGY (2014)
Rapid activation receptor- or IL-2-induced lytic granule convergence in human natural killer cells requires Src, but not downstream signaling
Ashley Mentlik James et al.
BLOOD (2013)
Characterization and Favorable in Vivo Properties of Heterodimeric Soluble IL-15•IL-15Rα Cytokine Compared to IL-15 Monomer
Elena Chertova et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
Circulating IL-15 exists as heterodimeric complex with soluble IL-15Rα in human and mouse serum
Cristina Bergamaschi et al.
BLOOD (2012)
IL-15:IL-15 receptor alpha superagonist complex: High-level co-expression in recombinant mammalian cells, purification and characterization
Kai-Ping Han et al.
CYTOKINE (2011)
The p110δ of PI3K plays a critical role in NK cell terminal maturation and cytokine/chemokine generation
Hailong Guo et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2008)
The biology of interleukin-2 and interleukin-15: implications for cancer therapy and vaccine design
Thomas A. Waldmann
NATURE REVIEWS IMMUNOLOGY (2006)
Soluble interleukin-15 receptor α (IL-15Rα)-sushi as a selective and potent agonist of IL-15 action through IL-15Rβ/γ -: Hyperagonist IL-15•IL-15Rα fusion proteins
E Mortier et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2006)
Membrane-bound and soluble IL-15/IL-15Rα complexes display differential signaling and functions on human hematopoietic progenitors
J Giron-Michel et al.
BLOOD (2005)
The roles of interleukin-15 receptor α:: Trans-presentation, receptor component, or both?
KS Schluns et al.
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY (2005)
Monocyte surface-bound IL-15 can function as an activating receptor and participate in reverse signaling
GG Neely et al.
JOURNAL OF IMMUNOLOGY (2004)
Coordinate expression and trans presentation of interleukin (IL)-15Rα and IL-15 supports natural killer cell and memory CD8+ T cell homeostasis
PR Burkett et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92
T Tonn et al.
JOURNAL OF HEMATOTHERAPY & STEM CELL RESEARCH (2001)
分享论文
